BIP3 Antibody

What is BIP3 antibody and what epitopes does it recognize?

BIP3 is a monoclonal antibody originally raised against birch pollen that recognizes high molecular weight (HMW) glycoproteins in birch and mugwort pollens, celery, and Apiaceae spices . This antibody primarily targets Api g 5, a celery allergen consisting of two polypeptides with molecular weights of 53 and 57 kDa, which carries N-glycans of the MUXF3 type . The epitope recognized by BIP3 appears to be predominantly protein in nature, with carbohydrate moieties playing only a minor role in recognition .

How is BIP3 related to the celery-mugwort-birch-spice syndrome?

BIP3 specifically recognizes the HMW allergens that are central to the celery-mugwort-birch-spice cross-reactivity syndrome . This syndrome involves allergic reactions to various plant-derived foods and pollens due to shared epitopes among their allergens. The epitopes recognized by BIP3 are also targets of human IgE in patients with this syndrome, suggesting that BIP3 mimics the binding pattern of allergic antibodies . This makes BIP3 a valuable tool for studying and potentially treating this clinical syndrome.

What methodological approaches can be used to study Api g 5 as a BIP3 target?

To verify Api g 5 as the BIP3 target, researchers should:

• Generate BIP3 mimotopes using phage display biopanning

• Immunize mice with the dominant mimotope phage clones

• Pool sera from immunized mice and test for IgG binding to:

  • Purified glycoprotein Api g 5

  • Horseradish peroxidase (HRP) as a model glycoprotein

  • Non-glycosylated control allergen (e.g., rPhl p 5)

• Measure induced IgG titers to Api g 5 using ELISA

• Perform inhibition studies to demonstrate that mimotope-induced antibodies can reduce human IgE binding to relevant allergens

What are mimotopes and how can they be generated for BIP3?

Mimotopes are peptides that mimic epitopes recognized by antibodies without sharing sequence identity with the original antigen. For BIP3, mimotopes can be generated through the following steps:

• Screen a random-peptide phage display library using BIP3 as the selecting antibody

• Perform multiple rounds of biopanning to enrich phage clones displaying peptides that bind to BIP3

• Monitor increasing titers of eluted phages (from 2.4×10^4 to 6.2×10^7) as evidence of successful enrichment

• Use colony screening assays to identify positive clones

• Sequence positive clones to determine the amino acid sequences of the displayed peptides

• Group sequences according to similarity to identify related mimotopes

How can we determine if BIP3 mimotopes actually mimic human IgE epitopes?

To validate that BIP3 mimotopes truly mimic human IgE epitopes:

• Perform inhibition studies by pre-incubating human serum containing birch-pollen specific IgE with selected phage-displayed mimotopes

• Test for reduction in IgE binding to HMW allergens compared to controls (unrelated phage clone, original phage library, or helper phage)

• Demonstrate that mimotopes can substantially decrease IgE binding to the HMW birch pollen proteins

• Compare the binding pattern of mimotope-induced IgG with that of human IgE from patients with celery-mugwort-birch-spice syndrome

What is the specific methodological workflow for generating and validating BIP3 mimotopes?

The precise workflow for generating and validating BIP3 mimotopes involves:

• Biopanning process:

  • Screen peptide phage display library with BIP3

  • Elute bound phages and amplify for subsequent rounds

  • Perform 3-4 rounds of selection, monitoring enrichment

• Enrichment monitoring:

  • Track total titers of eluted phages (increasing from 2.4×10^4 to 6.2×10^7)

  • Assess proportion of positive clones (increasing from 14/60 to 44/44)

• Sequence analysis and selection:

  • Sequence positive clones to identify dominant sequences

  • Group sequences phylogenetically by similarity

  • Select diverse clones for further studies

*clones selected for further studies

• Validation through inhibition studies:

  • Pre-incubate human serum with phage-displayed mimotopes

  • Demonstrate specific reduction in IgE binding to HMW allergens

  • Use unrelated phage controls to confirm specificity

How should researchers design immunization studies using BIP3 mimotopes?

For optimal immunization studies with BIP3 mimotopes:

• Animal selection and preparation:

  • Use BALB/c mice (8-10 weeks old, female)

  • House under pathogen-free conditions

  • Obtain ethical approval for animal experiments

• Immunization protocol:

  • Prepare phage-displayed mimotopes (CHKLRCDKAIA, CKASSCDTGHC, and CFFAWRSLPNCP)

  • Administer via subcutaneous route

  • Follow prime-boost regimen with appropriate intervals

  • Include proper control groups (unrelated phage clone, original library, or helper phage)

• Sample collection and processing:

  • Collect blood samples at defined intervals

  • Prepare serum for antibody analysis

  • Pool sera from mice immunized with the same mimotope for robust analysis

• Evaluation of immune response:

  • Test for specific IgG binding to HMW birch pollen allergens via Western blotting

  • Perform ELISA to measure specific IgG binding to Api g 5, HRP, and non-glycosylated control allergen

  • Determine antibody titers through serial dilutions

  • Test for inhibition of human IgE binding to relevant allergens

What role do carbohydrate moieties play in BIP3 epitope recognition and how can this be experimentally determined?

The role of carbohydrate moieties in the BIP3 epitope can be investigated through:

• Comparative binding studies:

  • Test binding of BIP3 and mimotope-induced antibodies to:

    • Api g 5 (contains both MMXF and MUXF types of complex N-glycans)

    • HRP (contains 6 xylose and fucose-containing glycans of MMXF type)

    • Non-glycosylated control proteins

• Analysis of glycan contribution:

  • Evaluate correlation between reactivity to Api g 5 and to MUXF3 (Manα1-6(Xylβ1-2)Manβ1-4GlcNAcβ1-4(Fucα1-3)GlcNAc)

  • Compare binding affinity to different glycoproteins with known glycan structures

• Enzymatic deglycosylation:

  • Treat Api g 5 with glycosidases to remove N-glycans

  • Compare binding of BIP3 to native and deglycosylated Api g 5

• Interpretation of results:

  • Strong binding to Api g 5 with minimal binding to HRP suggests predominance of protein epitope

  • Carbohydrates contribute to the Api g 5 IgE epitope but play a minor role in the BIP3 epitope

  • This approach distinguishes between protein, carbohydrate, and mixed epitopes

How can researchers assess the therapeutic potential of BIP3 mimotopes for allergen-specific immunotherapy?

To evaluate BIP3 mimotopes as candidates for immunotherapy:

• Immunogenicity assessment:

  • Determine if mimotopes induce robust IgG responses (titers reaching at least 1:500 to Api g 5)

  • Verify that induced antibodies specifically recognize relevant allergens

• Cross-reactivity profiling:

  • Test if mimotope-induced antibodies recognize multiple allergens involved in the syndrome

  • Evaluate binding to allergens from birch pollen, mugwort pollen, celery, and Apiaceae spices

• Inhibition of allergic response:

  • Assess if mimotope-induced antibodies can block IgE binding to allergens

  • Determine if these antibodies can inhibit IgE-mediated activation of effector cells

• Safety considerations:

  • Evaluate advantage of peptide mimotopes that induce blocking IgG without activating inflammatory allergen-specific T cells

  • Compare to traditional allergen immunotherapy for potential reduction in side effects

• Translational potential:

  • Consider bypassing uncertain aspects of carbohydrate moieties by translating the epitope into peptides

  • Evaluate mimotopes as candidates for epitope-specific immunotherapy within the celery-mugwort-birch-spice syndrome

What technical challenges exist in high-throughput bispecific antibody discovery that could be applied to BIP3-based therapeutics?

For developing BIP3-based therapeutics using high-throughput approaches:

• Single-cell functional screening pipeline:

  • Implement droplet microfluidic-based systems for compartmentalizing individual antibody-producing cells

  • Co-encapsulate with reporter cells to detect functional antibody variants

  • Achieve screening efficiency of up to 1.5 million variant library cells per run

  • Isolate rare functional clones at abundances as low as 0.008%

• Library design considerations:

  • Create complex libraries with varied scFvs, connecting linkers, and VL/VH orientations

  • Generate approximately 22,300 unique variants in a combinatorial approach

  • Include BIP3-derived binding domains in bispecific format with effector cell engagement domains

• Structural and compositional optimization:

  • Conduct unbiased interrogation of structural variables (affinity, epitope location, linker design)

  • Test relative orientations of binding antibody moieties combinatorially

  • Identify BiTEs with novel properties and design variable preferences for optimal functionality

• Mammalian cell-based expression systems:

  • Construct mammalian cell-based BsAb-variant expressing library cells

  • Engineer cells to encode a single copy of BsAb variant

  • Express target antigens (e.g., CD19 for model system) on the surface at levels comparable to disease-relevant cell lines

How should researchers select appropriate controls when working with BIP3 antibodies?

When designing experiments with BIP3 antibodies, researchers should include these critical controls:

• For biopanning and mimotope selection:

  • Original phage library (before selection)

  • Helper phage without inserted peptides

  • Unrelated phage clones displaying irrelevant peptides

• For immunization studies:

  • Mice immunized with unrelated phage clones

  • Mice immunized with original phage library or helper phage

  • Pre-immune sera from the same animals

• For binding studies:

  • Non-glycosylated control allergen (e.g., rPhl p 5)

  • Glycoproteins with different glycan structures (e.g., HRP)

  • Irrelevant proteins of similar molecular weight as Api g 5

• For inhibition studies:

  • Pre-incubation with unrelated antibodies or peptides

  • Dose-response curves with varying concentrations of inhibitors

  • Multiple patient sera to account for individual variability

What are the optimal protocols for validating BIP3 mimotope functionality in vitro?

For robust validation of BIP3 mimotope functionality:

• Binding assays:

  • ELISA: Coat plates with Api g 5, HRP, or control proteins

  • Flow cytometry: Test binding to cells expressing relevant allergens

  • Surface plasmon resonance: Determine binding kinetics and affinity

• Inhibition assays:

  • Pre-incubate human sera with mimotopes at various concentrations

  • Test for reduction in IgE binding to allergen extracts or purified allergens

  • Quantify inhibition as percentage reduction compared to controls

• Functional assays:

  • Basophil activation test: Measure inhibition of allergen-induced basophil activation

  • T cell proliferation assays: Verify that mimotopes don't activate allergen-specific T cells

  • Mast cell degranulation assays: Test if mimotope-induced antibodies can block allergen-induced degranulation

• Data analysis and interpretation:

  • Determine EC50 values for inhibition

  • Compare inhibitory potency of different mimotopes

  • Correlate inhibitory capacity with sequence features of mimotopes

How does the storage and handling of BIP3 antibodies affect experimental outcomes?

Proper storage and handling of BIP3 antibodies is critical for experimental success:

• Storage conditions:

  • Store lyophilized antibody at -20°C for one year from receipt date

  • After reconstitution, store at 4°C for up to one month

  • For longer storage after reconstitution, aliquot and store at -20°C for up to six months

  • Avoid repeated freeze-thaw cycles that can degrade antibody activity

• Reconstitution protocol:

  • Add precisely 0.2 ml of distilled water to lyophilized antibody

  • This yields a concentration of 500 μg/ml

  • Allow complete dissolution before use

  • Consider buffer composition (typically contains trehalose, NaCl, and phosphate)

• Quality control measures:

  • Verify antibody functionality after each reconstitution

  • Include positive and negative controls in each experiment

  • Consider testing antibody binding at multiple dilutions to ensure optimal signal-to-noise ratio

  • Document lot-to-lot variations that might affect experimental outcomes

What technical considerations are important when using BIP3 for Western blotting applications?

For optimal Western blotting results with BIP3:

• Sample preparation:

  • Prepare protein extracts from relevant sources (birch pollen, mugwort pollen, celery, Apiaceae spices)

  • Use appropriate lysis buffers that preserve glycoprotein integrity

  • Include protease inhibitors to prevent degradation

• Electrophoresis conditions:

  • Use SDS-PAGE gels of appropriate percentage (typically 10-12% for HMW allergens)

  • Consider native PAGE for certain applications to preserve conformational epitopes

  • Include molecular weight markers spanning 40-60 kDa range to identify Api g 5

• Transfer and blocking:

  • Use PVDF membranes for optimal protein binding

  • Block with protein-free blocking buffers to avoid cross-reactivity

  • Consider specialized blocking reagents for glycoprotein applications

• Antibody incubation:

  • Optimize antibody dilution (typically starting at 1:500-1:1000)

  • Incubate at 4°C overnight for maximum sensitivity

  • Use appropriate secondary antibodies with minimal background

• Detection and analysis:

  • Use high-sensitivity chemiluminescent substrates for detection

  • Consider longer exposure times for weaker signals

  • Perform densitometric analysis to quantify binding intensity

How can researchers integrate BIP3 antibody research with high-throughput bispecific antibody discovery platforms?

To leverage high-throughput platforms for BIP3-related research:

• Platform adaptation:

  • Incorporate BIP3 binding domains into bispecific antibody formats

  • Engineer T cell engagement domains (e.g., anti-CD3) coupled with BIP3-derived targeting domains

  • Develop BIP3xCD3 bispecific T cell engagers (BiTEs) as potential therapeutics

• Library construction:

  • Generate combinatorial libraries varying:

    • BIP3-derived scFv sequences

    • Connecting linker lengths and compositions

    • VL/VH orientations

  • Optimize expression vectors for mammalian cell-based systems

• Screening methodology:

  • Implement droplet microfluidic-based functional screening

  • Co-encapsulate BiTE-producing cells with appropriate reporter cells

  • Use multiplexed orthogonal assay chemistry for improved fidelity

  • Apply multi-point detection and droplet-indexing strategies

• Downstream characterization:

  • Sequence isolated clones to identify unique variants

  • Characterize novel properties of selected BiTEs

  • Derive design principles based on sequence-structure-function relationships

  • Scale up production of promising candidates for preclinical testing